Posted by admin on Jul 23rd, 2022

Endo International plc (NASDAQ:ENDP – Get Rating) (TSE:ENL) has earned a consensus recommendation of “Hold” from the seven analysts that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and one has assigned a buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $3.00.

Several analysts have recently weighed in on ENDP shares. StockNews.com began coverage on shares of Endo International in a research report on Thursday. They set a “hold” rating for the company. BMO Capital Markets dropped their price objective on Endo International from $4.00 to $2.00 in a report on Monday, May 9th. Piper Sandler downgraded Endo International from a “neutral” rating to an “underweight” rating and reduced their target price for the company from $3.00 to $1.00 in a report on Friday, May 6th. Finally, Barclays dropped their price target on Endo International from $2.00 to $1.00 in a research note on Monday, May 9th.

Endo International stock opened at $0.40 on Wednesday. The stock has a market cap of $94.96 million, a PE ratio of -0.13 and a beta of 1.11. The stock’s fifty day moving average is $0.48 and its two-hundred day moving average is $1.89. Endo International has a 1-year low of $0.28 and a 1-year high of $7.07.

Endo International (NASDAQ:ENDP – Get Rating) (TSE:ENL) last released its quarterly earnings data on Thursday, May 5th. The company reported $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.44 by $0.22. The business had revenue of $652.26 million for the quarter, compared to the consensus estimate of $637.09 million. Endo International had a negative return on equity of 72.22% and a negative net margin of 24.82%. The business’s revenue for the quarter was down 9.1% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.73 EPS. On average, research analysts expect that Endo International will post 0.78 earnings per share for the current fiscal year.

A number of hedge funds have recently added to or reduced their stakes in ENDP. New York State Common Retirement Fund raised its stake in shares of Endo International by 161.7% during the first quarter. New York State Common Retirement Fund now owns 426,139 shares of the company’s stock worth $984,000 after purchasing an additional 263,322 shares during the last quarter. Yousif Capital Management LLC acquired a new stake in shares of Endo International in the 4th quarter worth $814,000. Jackson Creek Investment Advisors LLC purchased a new stake in shares of Endo International in the fourth quarter valued at about $681,000. Mitsubishi UFJ Trust & Banking Corp increased its stake in shares of Endo International by 34.0% during the first quarter. Mitsubishi UFJ Trust & Banking Corp now owns 438,499 shares of the company’s stock worth $1,013,000 after acquiring an additional 111,380 shares during the period. Finally, State of Tennessee Treasury Department raised its holdings in Endo International by 44.5% during the first quarter. State of Tennessee Treasury Department now owns 217,468 shares of the company’s stock worth $502,000 after purchasing an additional 66,966 shares in the last quarter. 80.39% of the stock is owned by institutional investors and hedge funds.

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology.

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.

ATCO Ltd. (OTCMKTS:ACLLF) Receives $48.92 Consensus Price Target from Analysts

Brokerages Set boohoo group plc (LON:BOO) Price Target at GBX 188.89